Pharmacological role and clinical effect of low-dose recombinant human interferon α2a combined with oseltamivir in the treatment of viral pneumonia in children
Objective To investigate the pharmacological role and clinical effect of low-dose recombinant human interferon α2a(rhIFNα2a)combined with oseltamivir in the treatment of viral pneumonia in children.Methods 99 children with viral pneumonia were selected as the observation objects,and randomized into the control group(to be treated with oseltamivir),low-dose group(to be treated with 20 μg/d rhIFNα2a and oseltamivir)and high-dose group(to be treated with 40 μg/d rhIFNα2a and oseltamivir),with 33 cases in each group.The control group was treated with oseltamivir orally,low-dose group was given 20 μg/d recombinant human interferon α2a combined with oseltamivir,and high-dose group received 40 μg/d recombinant human interferon α2a combined with oseltamivir.The clinical efficacy and related indicators after 7 days of treatment and levels of serum immunoglobulins,inflammatory factors and oxidative damage indexes before treatment and after 7 days of treatment were compared among the three groups.Results The total effective rate in low-dose(84.85%)and high-dose groups(87.88%)was significantly higher than that in the control group(60.61%)(P＜0.05).The fever time,cough time,hospitalization time and average course of disease in low-dose and high-dose groups were significantly shorter than those in the control group(P＜0.05),but there were no statistical differences in the above indexes among the three groups and between low-dose group and high-dose group(P＞0.05).The remission time of symptoms(fever and cough),hospitalization time and average course of disease in the low and high dose groups were sighificantly shorter than those in the control group(P＜0.05).There was no significant difference between the low and high dose groups(P＞0.05).The levels of serum IgM and IgG and serum SP-D,TLR2 and MDA in the three groups after 7 days of treatment were significantly lower than those before treatment(P＜0.05)while the level of serum SOD was significantly higher(P＜0.05),and the changes in low-dose and high-dose groups were significantly greater than those in the control group(P＜0.05),but there were no statistical differences between low-dose group and high-dose group(P＞0.05).Conclusion Low-dose and high-dose rhIFNα2a combined with oseltamivir respectively have the same efficacy in the treatment of viral pneumonia in children,which is better than single oseltamivir treatment.They can improve the disease condition,enhance the immune function of children,and significantly reduce the degree of inflammatory response and lipid peroxidation damage.However,the adverse reactions of low-dose recombinant human interferon α2a are fewer.
Viral pneumonia in childrenRecombinant human interferon α2aLow-doseOseltamivirInflammatory responseLipid peroxidation damage
万方数据
维普
